Skip to main content

Table 1 Parp-inhibitors on Clinical Trials

From: BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Parp-inhibitors

Pharmaceutical Company

Clinical development

Olaparib

(AZD2281)

AstraZeneca

Breast, ovarian and prostate cancer BRCA1-BRCA2 related

Breast cancer

Ovarian cancer

Pacreatic cancer

Colorectal cancer

Melanoma neoplasm

Unspecified adult solid tumors

BSI-201

BiPar Sciences Inc.

Uterine cancer

Brain neoplasm

Triple negative breast cancer

ABT-888

Abbott

Metastatic Melanoma

Skin cancer

Breast Cancer

Ovarian Cancer

Primary Peritoneal Cancer

Fallopian Tube Cancer

MK 4827

Merck & Co. Inc.

BRCA-related ovarian cancer

Ovarian cancer

Solid tumors